---
category: news
title: "Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy"
excerpt: "Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the 24-month, Phase 3 OAKS and DERBY studies evaluating SYFOVRE™ (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)."
publishedDateTime: 2023-04-23T23:50:00Z
originalUrl: "https://it.tmcnet.com/news/2023/04/23/9799735.htm"
webUrl: "https://it.tmcnet.com/news/2023/04/23/9799735.htm"
type: article
quality: 0
heat: 0
published: false

provider:
  name: TMCnet
  domain: tmcnet.com

topics:
  - AI in Healthcare
  - AI

secured: "ih19tAjuUd9Y4SwCZzX2fdGI+bvR1hnqOdQgaL0tWLVmNFm5KFdwt4EM27vtvTI9BLPQFEUaHWHzkjr5jHIwATJkKxLdYbzcpyxsRixruT+WdXCBUuPlKUc1cO63+C1R3vq/AQCkcTAajOuT0VDMdxRoMQgQl4kG3nN9Kz4JJ20iOK8bPVLJqqDf7Ir/K613fqqT9OBfv03qL5LG3BvKmDPB3wNRi3rj3FIXa+ypq4G9RC46eGVQsoni/2sXRPaOX3qOrw7GD9I55A8e0geNJLDJQtLJ4dIYMkAePt73TXDTcJ1zgbQNiGJDzs8mGREG1kNf3Wo2UfRMFfrOpg07c4yDf7E2RoZtOahNndU+MkU=;kE6jGNj5fkxYU2SCktahYA=="
---

